VERICEL CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
VERICEL CORPORATION (VCEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $19.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-09-30 was $76.83M.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-06-30 was $76.83M.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-03-31 was $76.69M.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $19.40M, a 61.28% decline from fiscal 2024.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $50.10M, a 568.00% increase from fiscal 2023.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $7.50M, a 38.89% increase from fiscal 2022.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $5.40M, a 86.33% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $19.40M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $50.10M 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | $7.50M 10-K · filed 2026-02-26 | ||||
| 2022-12-31 | $5.40M 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $39.50M 10-K · filed 2024-02-29 | ||||
| 2020-12-31 | $10.50M 10-K · filed 2023-02-23 | ||||
| 2019-12-31 | $16.10M 10-K · filed 2022-02-24 | $12.40M 10-K · filed 2020-02-25 | |||
| 2018-12-31 | $11.40M 10-K · filed 2021-02-24 | $10.30M 10-K · filed 2020-02-25 | |||
| 2017-12-31 | $700.00K 10-K · filed 2020-02-25 | ||||
| 2016-09-30 | $76.83M 10-Q · filed 2016-11-07 | $153.65M derived: sum of 2 quarters · filed 2016-11-07 | $230.34M derived: sum of 3 quarters · filed 2016-11-07 | ||
| 2016-06-30 | $76.83M 10-Q · filed 2016-08-08 | $153.51M derived: sum of 2 quarters · filed 2016-08-08 | |||
| 2016-03-31 | $76.69M 10-Q · filed 2016-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |